Richard William Scalzo
Known title: Chief Financial OfficerCIK: 0001789545
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.
Transaction History
| CBIO | ▼ Sell | Open Market | 568 | $10K | 9/16/2026 | View on chart |
| CBIO | ▼ Sell | Open Market | 1,112 | $20K | 6/22/2026 | View on chart |
| CBIO | ▲ Buy | Grant | 14,422 | — | 12/15/2025 | View on chart |
| CBIO | ▲ Buy | Grant | 5,000 | — | 12/15/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 1,343 | $15K | 3/11/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 917 | $11K | 3/5/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 2,488 | $35K | 2/18/2025 | View on chart |
| DYN | ▼ Sell | Open Market | 1,455 | $41K | 12/11/2024 | View on chart |
| DYN | ▲ Buy | Grant | 32,700 | $0 | 12/4/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 2,735 | $77K | 11/18/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,390 | $48K | 9/18/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,468 | $47K | 9/11/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 6,552 | $71K | 9/6/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 124,374 | $4.0M | 9/6/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,700 | $55K | 9/6/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 6,502 | $36K | 9/6/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 3,353 | $19K | 9/6/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 34,833 | $662K | 9/6/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 16,696 | $219K | 9/6/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 18,750 | $201K | 9/6/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 29,792 | $256K | 9/6/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 2,442 | $110K | 8/19/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 310 | $14K | 8/19/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,331 | $42K | 6/11/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,590 | $48K | 6/10/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 2,126 | $60K | 5/16/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 462 | $13K | 5/16/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,082 | $28K | 3/11/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,590 | $40K | 3/11/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 30,755 | $778K | 3/8/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 55,208 | $1.5M | 3/8/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 289 | $8K | 3/8/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 17,333 | $96K | 3/8/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 68,919 | $382K | 3/8/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 2,273 | $59K | 3/7/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 9,311 | $10K | 3/1/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 8,747 | $247K | 3/1/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 564 | $16K | 3/1/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 3,429 | $4K | 2/29/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 3,429 | $94K | 2/29/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 13,000 | $13K | 1/26/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 13,000 | $316K | 1/26/2024 | View on chart |
| DYN | ▲ Buy | Option Exercise | 13,000 | $13K | 1/3/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 13,000 | $245K | 1/3/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 2,376 | $29K | 12/14/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,380 | $15K | 12/11/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,872 | $22K | 12/6/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 681 | $8K | 12/4/2023 | View on chart |
| DYN | ▲ Buy | Grant | 89,742 | $0 | 11/15/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,290 | $12K | 9/18/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,397 | $15K | 9/12/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 10,000 | $120K | 6/15/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,390 | $17K | 6/13/2023 | View on chart |
| DYN | ▲ Buy | Option Exercise | 40,000 | $41K | 6/13/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 40,000 | $516K | 6/13/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,311 | $17K | 3/14/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 312 | $3K | 12/12/2022 | View on chart |
| DYN | ▲ Buy | Grant | 31,000 | $0 | 12/9/2022 | View on chart |
| DYN | ▼ Sell | Other | 840 | $12K | 9/20/2022 | View on chart |
| DYN | ▼ Sell | Other | 326 | $5K | 9/15/2022 | View on chart |
| DYN | ▼ Sell | Other | 333 | $2K | 6/14/2022 | View on chart |
| DYN | ▼ Sell | Open Market | 308 | $3K | 3/11/2022 | View on chart |
| DYN | ▲ Buy | Grant | 16,696 | $0 | 12/10/2021 | View on chart |
| DYN | ▼ Sell | Open Market | 492 | $8K | 9/21/2021 | View on chart |
| DYN | ▼ Sell | Open Market | 367 | $6K | 9/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001
Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.